Effects of calcium channel antagonists on the motivational effects of nicotine and morphine in conditioned place aversion paradigm

Behavioural Brain Research

Volumn 228, Issue 1, 2012, Pages 144-150

  Budzynska, Barbara ^a   Polak, Piotr ^a   Biala, Grazyna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Calcium channel antagonists; Morphine; Nicotine; Place aversion; Rats

Indexed keywords

CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; FLUNARIZINE; MECAMYLAMINE; MORPHINE; NALOXONE; NICOTINE; NIMODIPINE; SODIUM CHLORIDE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVERSIVE BEHAVIOR; AVOIDANCE BEHAVIOR; CONDITIONING; CONTROLLED STUDY; MALE; MOTIVATION; NONHUMAN; OPIATE ADDICTION; PLACE AVERSION; PRIORITY JOURNAL; RAT; REINFORCEMENT; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

ANIMALS; AVOIDANCE LEARNING; CALCIUM CHANNEL BLOCKERS; DRUG ADMINISTRATION SCHEDULE; FLUNARIZINE; MALE; MORPHINE; MOTIVATION; NICOTINE; NIMODIPINE; RATS; RATS, WISTAR; SUBSTANCE WITHDRAWAL SYNDROME; VERAPAMIL;

EID: 84055181353     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.12.003     Document Type: Article

References (75)

1. Hyman S.E., Malenka R.C. Addiction and the brain: the neurobiology of compulsion and its persistence. Nat Rev Neurosci 2001, 2:695-703.
2. Robinson T.E., Berridge K.C. Addiction. Annu Rev Psychol 2003, 54:25-53.
3. Markou A., Kosten T.R., Koob G.F. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 1998, 18:135-174.
4. Le Foll B., Goldberg S.R. Effects of nicotine in experimental animals and humans: an update on addictive properties. Handb Exp Pharmacol 2009, 192:335-367.
5. Nestler E.J., Aghajanian G.K. Molecular and cellular basis of addiction. Science 1997, 278:58-63.
6. O'Dell T.J., Christensen B.N. Mecamylamine is a selective noncompetitive antagonist of N-methyl-d-aspartate- and aspartate induced currents in horizontal cells dissociated from the catfish retina. Neurosci Lett 1988, 94:93-98.
7. Stolerman I.P., Shoaib M. The neurobiology of tobacco addiction. Trends Pharmacol Sci 1991, 12:467-473.
8. Stinus L., Caille S., Koob G.F. Opiate withdrawal-induced place aversion lasts for up to 16 weeks. Psychopharmacology 2000, 149:115-120.
9. Zaniewska M., Przegalinski E., Filip M. Nicotine dependence - human and animal studies, current pharmacotherapies and future perspectives. Pharmacol Rep 2009, 61:957-965.
10. Isola R., Vogelsberg V., Wemlinger T.A., Neff N.H., Hadjiconstantinou M. Nicotine abstinence in the mouse. Brain Res 1999, 850:189-196.
11. Schulteis G., Heyser C.J., Koob G.F. Differential expression of response-disruptive and somatic indices of opiate withdrawal during the initiation and development of opiate dependence. Behav Pharmacol 1999, 10:235-242.
12. Wilmouth C.E., Spear L.P. Withdrawal from chronic nicotine in adolescent and adult rats. Pharmacol Biochem Behav 2006, 85:648-657.
13. Koob G.F., Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997, 278:52-58.
14. Schulteis G., Heyser C.J., Koob G.F. Opiate withdrawal signs precipitated by naloxone following a single exposure to morphine: potentiation with a second morphine exposure. Psychopharmacology 1997, 129:56-65.
15. Schechter M.D., Calcagnetti D.J. Continued trends in the conditioned place preference literature from 1992 to 1996, inclusive, with a cross-indexed bibliography. Neurosci Biobehav Rev 1998, 22:827-846.
16. Azar M.R., Jones B.C., Schulteis G. Conditioned place aversion is a highly sensitive index of acute opioid dependence and withdrawal. Psychopharmacology 2003, 170:42-50.
17. Jackson K.J., Kota D.H., Martin B.R., Damaj M.I. The role of various nicotinic receptor subunits and factors influencing nicotine conditioned place aversion. Neuropharmacology 2009, 56:970-974.
18. Solecki W., Turek A., Kubik J., Przewlocki R. Motivational effects of opiates in conditioned place preference and aversion paradigm - a study in three inbred strains of mice. Psychopharmacology 2009, 207:245-255.
19. Tzschentke T.M. Measuring reward with the conditioned place preference paradigm: a comparative review of drug effects, recent progress and new issues. Prog Neurobiol 1998, 56:613-672.
20. Spanagel R., Herz A., Shippenberg T.S. The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J Neurochem 1990, 55:1734-1740.
21. Biala G., Weglinska B. Blockade of the expression of mecamylamine-precipitated nicotine withdrawal by calcium channel antagonists. Pharmacol Res 2005, 51:483-488.
22. Antkiewicz-Michaluk L., Michaluk J., Romańska I., Vetulani J. Reduction of morphine dependence and potentiation of analgesia by chronic co-administration of nifedipine. Psychopharmacology 1993, 11:457-464.
23. Biala G. Calcium channel antagonists suppress nicotine-induced place preference and locomotor sensitization in rodents. Pol J Pharmacol 2003, 55:327-335.
24. Biala G., Weglinska B. Calcium channel antagonists attenuate cross-sensitization to the rewarding and/or locomotor effects of nicotine, morphine and MK-801. J Pharm Pharmacol 2004, 56:1021-1028.
25. Biala G., Budzynska B. Calcium-dependent mechanisms of the reinstatement of nicotine conditioned place preference by drug priming in rats. Pharmacol Biochem Behav 2008, 89:116-125.
26. Biala G., Budzynska B. Reinstatement of nicotine-conditioned place preference by drug priming: effects of calcium channel antagonists. Eur J Pharmacol 2006, 537:85-93.
27. Dolin S.J., Little H.J. Are changes in neuronal calcium channels involved in ethanol tolerance. J Pharmacol Exp Ther 1989, 250:985-991.
28. Zharkovsky A., Totterman A.M., Moisio J., Ahtee L. Concurrent nimodipine attenuates the withdrawal signs and the increase of cerebral dihydropyridine binding after chronic morphine treatment in rats. Arch Pharmacol 1993, 347:483-486.
29. Vargas-Perez H., Ting A.K.R.A., Heinmiller A., Sturgess J.E., van der Kooy D. A test of the opponent-process theory of motivation using lesions that selectively block morphine reward. Eur J Neurosci 2007, 25:3713-3718.
30. Mucha R.F., Herz A. Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology 1985, 86:274-280.
31. Hand T.H., Koob G.F., Stinus L., Le Moal M. Aversive properties of opiate receptor blockade: evidence for exclusively central mediation in naive and morphine-dependent rats. Brain Res 1988, 474:364-368.
32. Li Y., Liu X., Chen H., Deng H., Xiang X., Chen H., et al. Development, extinction and reinstatement of morphine withdrawal-induced conditioned place aversion in rats. Addict Biol 2007, 12:470-477.
33. Popik P., Danysz W. Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by N-methyl-d-aspartate receptor antagonist, memantine. J Pharmacol Exp Ther 1997, 280:854-865.
34. Suzuki T., Ise Y., Maeda J., Misawa M. Mecamylamine-precipitated nicotine-withdrawal aversion in Lewis and Fisher 344 inbred rat strain. Eur J Pharmacol 1999, 369:159-162.
35. Lu K., Chen H., Su W., Ge X., Yue W., Su F., et al. Role of withdrawal in reinstatement of morphine-conditioned place preference. Psychopharmacology 2005, 181:90-100.
36. Jackson K.J., Martin B.P., Changeux J.P., Damaj M.I. Differential role of nicotinic acetylcholine receptor subunits in physical and affective withdrawal signs. J Pharmacol Exp Ther 2008, 325:302-312.
37. Guillem K., Vouillac C., Koob G.F., Cador M., Stinus L. Monoamine oxidase inhibition dramatically prolongs the duration of nicotine withdrawal-induced place aversion. Biol Psychiatry 2008, 63:158-163.
38. Hughes J.R., Gust S.W., Skoog K., Keenan R.M., Fenwick J.W. Symptoms of tobacco withdrawal. A replication and extension. Arch Gen Psychiatry 1991, 48:52-59.
39. Kenny P.J., Markou A. Conditioned nicotine withdrawal profoundly decreases the activity of brain reward systems. J Neurosci 2005, 25:6208-6212.
40. Watkins S.S., Stinus L., Koob G.F., Markou A. Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects. J Pharmacol Exp Ther 2000, 292:1053-1064.
41. Shram M.J., Siu E.C.K., Li Z., Tyndale R.F., Lê A.D. Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats. Psychopharmacology 2008, 198:181-190.
42. Ward J., Cockcroft V., Lunt G., Smillie F., Wonnacott S. Methyllycaconitine: a selective probe for neuronal α-bungarotoxin binding sites. FEBS Lett 1990, 270:45-48.
43. Marubio L.M., Gardier A.M., Durier S., David D., Klink R., Arroyo- Jimenez M.M., et al. Effects of nicotine in the dopaminergic system of mice lacking the alpha 4 subunit of neuronal nicotinic acetylcholine receptors. Eur J Neurosci 2003, 17:1327-1337.
44. Maskos U., Molles B.E., Pons S., Besson M., Guiard B.P., Guilloux J.P., et al. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 2005, 436:103-107.
45. Grenhoff J., Aston-Jones G., Svensson T.H. Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol Scand 1986, 128:351-358.
46. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 2000, 393:295-314.
47. Dani J.A., De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 2001, 70:439-446.
48. Pontieri F.E., Tanda G., Orzi F., Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996, 382:255-257.
49. Liu Z.H., Jin W.Q. Decrease of ventral tegmental area dopamine neuronal activity in nicotine withdrawal rats. Neuroreport 2004, 15:1479-1481.
50. Hildebrand B.E., Nomikos G.G., Hertel P., Schilström B., Svensson T.H. Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res 1998, 779:214-225.
51. Araki H., Kawakami K.Y., Jin C., Suemaru K., Kitamura Y., Nagata M., et al. Nicotine attenuates place aversion induced by naloxone in single-dose, morphine-treated rats. Psychopharmacology (Berl) 2004, 171:398-404.
52. Rezayof A., Razavi S., Haeri-Rohani H., Rassouli Y., Zarrindast M.R. GABA(A) receptors of hippocampal CA1 regions are involved in the acquisition and expression of morphine-induced place preference. Eur Neuropsychopharmacol 2007, 17:24-31.
53. Rada P., Mark G.P., Pothos E., Hoebel B.G. Systemic morphine simultaneously decreases extracellular acetylcholine and increases dopamine in the nucleus accumbens of freely moving rats. Neuropharmacology 1991, 30:1133-1136.
54. Skoubis P.D., Matthes H.W., Walwyn W.M., Kieffer B.L., Maidment N.T. Naloxone fails to produce conditioned place aversion in mu-opioid receptor knock-out mice. Neuroscience 2001, 106:757-763.
55. Shippenberg T.S., Bals-Kubik R. Involvement of the mesolimbic dopamine system in mediating the aversive effects of opioid antagonists in the rat. Behav Pharmacol 1995, 6:99-106.
56. Acquas E., Di Chiara G. Depression of mesolimbic dopamine transmission and sensitization to morphine during opiate abstinence. J Neurochem 1992, 58:1620-1625.
57. Rossetti Z.L., Hmaidan Y., Gessa G.L. Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur J Pharmacol 1992, 221:227-234.
58. North R.A. Opioid receptors types and membrane ion channels. Trends Neurosci 1986, 9:114-117.
59. Kapur A., Yeckel M.F., Gray R., Johnston D. L-type calcium channels are required for one form of hippocampal mossy fiber cLTP. J Neurophysiol 1998, 79:2181-2190.
60. Wickens J.R., Abraham W.C. The involvement of L-type calcium channels in heterosynaptic long-term depression in the hippocampus. Neurosci Lett 1991, 130:128-132.
61. Haller V.L., Bernstein M.A., Welch S.P. Chronic morphine treatment decreases the Cav1.3 subunit of the L-type calcium channel. Eur J Pharmacol 2008, 578:101-107.
62. Karler R., Turkanis S.A., Partlow L.M., Calder L.D. Calcium channel blockers and behavioral sensitization. Life Sci 1991, 49:165-170.
63. Anderson S.M., Famous K.R., Sadri-Vakili G., Kumaresan V., Schmidt H.D., Bass C.E., et al. CaMKII: a biochemical bridge linking accumbens dopamine and glutamate systems in cocaine seeking. Nat Neurosci 2008, 11:344-353.
64. Narita M., Matsumura Y., Ozaki S., Ise Y., Yajima Y., Suzuki T. Role of the calcium/calmodulin-dependent protein kinase II (CaMKII) in the morphine-induced pharmacological effects in the mouse. Neuroscience 2004, 126:415-421.
65. Picciotto M.R., Zoli M., Rimondini R., Lena C., Marubio L.M., Pich E.M., et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 1998, 391:173-177.
66. Mansvelder H.D., McGehee D.S. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron 2000, 27:349-357.
67. Mansvelder H.D., McGehee D.S. Cellular and synaptic mechanisms of nicotine addiction. J Neurobiol 2002, 53:606-617.
68. He J., Deng C.Y., Chen R.Z., Zhu X.N., Yu J.P. Long-term potentiation induced by nicotine in CA1 region hippocampal slice is Ca(2+)-dependent. Acta Pharmacol Sin 2000, 21:429-432.
69. Jackson K.J., Damaj M.I. L-type calcium channel and calcium/calmodulin-dependent kinase II differentially mediate behaviors associated with nicotine withdrawal in mice. JPET 2009, 330:152-161.
70. Shibasaki M., Kurokawa K., Ohkuma S. Role of alpha2/delta subunit in the development of morphine-induced rewarding effect and behavioral sensitization. Neuroscience 2009, 163:731-734.
71. ++ channels during opioid tolerance and supersensitivity in rats. J Pharmacol Exp Ther 1995, 274:1538-1544.
72. i) in brain and spinal cord of morphine-tolerant rats and mice. Pharmacol Biochem Behav 1995, 1:57-63.
73. Kuzmin A.V., Patkina N.A., Zvartau E.E. Analgesic and reinforcing effects of morphine in mice. Influence of Bay K-8644 and nimodipine. Brain Res 1994, 652:1-8.
74. 2+-channel blockers potentiate morphine analgesia in mice. Life Sci 2003, 73:2873-2881.
75. 2+ channels due to phosphorylation by cAMPdependent protein kinase. Nature 1993, 364:240-243.